Torrent Pharmaceuticals Ltd Share Price
As on 07 June 2026 at 00:43 IST
Torrent Pharmaceuticals Q1 FY26 Results:
Net profit for the period increased 20% to ₹548 crores in Q1 FY26, from ₹457 crores in Q1 FY25. Total income for the quarter increased 9% year-on-year to ₹3141 crores from ₹2883 crores.
About Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company. It engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. Founded in the year 1959, the company has decades of experience in the industry. The headquarters of the company is located in Ahmedabad, Gujarat, India. Torrent Pharmaceuticals' main products include branded and unbranded generic pharmaceuticals. They have a significant presence in various therapeutic areas such as gastrointestinal, cardiovascular, central nervous system, women's healthcare, gynaecology, diabetology, oncology, pain management, and anti-infective segments. Torrent Pharmaceuticals Ltd. falls under the pharmaceuticals sector. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
2.07%
Over 6 Months
14.34%
Over 1 Year
38.34%
Over 3 Years
144.47%
Torrent Pharmaceuticals Ltd Summary
Close ₹4,339.90
Open ₹4,389
High ₹4,425
Low ₹4,328.10
Volume 5,95,200
Net Turnover (in Cr) ₹259.79
52Wk High ₹4,712.90
52Wk Low ₹3,108.80
52Wk High / Low
3,108.80
4,712.90
Torrent Pharmaceuticals Ltd Fundamentals
Key Financial Data
Market Cap (in Cr) ₹1,46,881.94
EPS (TTM) 65.37
Book Value (BV) 249.73
Div. Yield 0.88 %
P/E (TTM) 66.99
Price/Book Value 17.37
Delivery % 61.23 %
Face Value 5
Key Ratios
PE Ratio 65.18
PB Ratio 16.90
EV to Sales 14.66
PEG Ratio 4.05
ROA 9.45
ROE 27.32
Debt-Equity 1.05
Net Profit Margin 20.46
Operating Profit Margin 37.35
Torrent Pharmaceuticals Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Revenue | 13,886.15 | 11,539.36 | 10,785.75 | 9,665.29 | 8,704.60 |
| Total Expenses | 10,925.21 | 8,842.34 | 8,522.02 | 7,818.13 | 6,993.99 |
| Profit Before Tax | 2,872.19 | 2,672.81 | 2,352.11 | 1,847.16 | 1,225.91 |
| Profit After Tax | 2,138.18 | 1,911.25 | 1,656.38 | 1,245.23 | 777.18 |
| Operating Profit After Depreciation | 3,346.01 | 2,949.33 | 2,617.29 | 2,180.60 | 1,965.67 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Fixed Assets | 33,361.71 | 8,057.78 | 8,217.82 | 8,198.61 | 6,508.13 |
| Total Non Current Assets | 34,920.07 | 9,367.17 | 9,449.10 | 9,698.13 | 7,934.85 |
| Total Current Assets | 9,391.89 | 5,622.57 | 5,611.48 | 5,313.72 | 5,164.99 |
| Total Assets | 44,311.96 | 14,989.74 | 15,060.58 | 15,011.85 | 13,099.84 |
| Total Shareholder's Fund | 8,388.43 | 7,590.69 | 6,856.15 | 6,198.07 | 5,952.95 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 3,022.71 | 2,585.11 | 3,266.08 | 2,368.13 | 1,802.99 |
| Net Cash Used In Investing Activities | -12,629.59 | -548.78 | -159.83 | -2,335.36 | -196.10 |
| Net Cash Used In Financing Activities | 10,150.60 | -2,297.99 | -2,779.64 | 77.36 | -1,781.05 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Total Revenue | 10,729.92 | 9,713.94 | 8,624.26 | 7,777.08 | 6,946.49 |
| Total Expenses | 7,763.29 | 7,079.55 | 6,707.69 | 6,200.06 | 5,480.28 |
| Profit Before Tax | 2,896.61 | 2,610.18 | 1,916.57 | 1,577.02 | 1,466.21 |
| Profit After Tax | 2,191.59 | 1,888.06 | 1,357.08 | 1,051.39 | 991.45 |
| Operating Profit After Depreciation | 3,307.59 | 2,847.79 | 2,219.61 | 1,874.70 | 1,702.50 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Fixed Assets | 7,392.63 | 7,590.29 | 8,008.21 | 7,994.88 | 6,275.21 |
| Total Non Current Assets | 20,922.49 | 8,492.96 | 8,635.53 | 8,944.85 | 7,092.51 |
| Total Current Assets | 4,891.04 | 4,348.80 | 3,741.06 | 3,927.08 | 4,060.05 |
| Total Assets | 25,813.53 | 12,841.76 | 12,376.59 | 12,871.93 | 11,152.56 |
| Total Shareholder's Fund | 8,452.17 | 7,592.50 | 6,828.76 | 6,455.96 | 6,345.42 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 2,730.83 | 2,574.50 | 2,893.10 | 2,265.41 | 2,140.10 |
| Net Cash Used In Investing Activities | -12,990.20 | -470.09 | -296.07 | -2,325.75 | -159.70 |
| Net Cash Used In Financing Activities | 10,225.23 | -2,104.46 | -2,577.57 | 80.74 | -1,977.27 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 4,197 | 3,303 | 3,302 | 3,178 | 2,959 |
| Total Expenses | 2,841 | 2,215 | 2,219 | 2,146 | 1,995 |
| Profit Before Tax | 529 | 814 | 791 | 738 | 665 |
| Profit After Tax | 364 | 635 | 591 | 548 | 498 |
| Operating Profit after Depreciation | 1,339 | 1,075 | 1,056 | 995 | 946 |
| Particulars (in ₹ Cr.) | 2026-03 | 2025-12 | 2025-09 | 2025-06 | 2025-03 |
|---|---|---|---|---|---|
| Total Revenue | 2,735 | 2,599 | 2,762 | 2,616 | 2,433 |
| Total Expenses | 1,732 | 1,599 | 1,690 | 1,637 | 1,565 |
| Profit Before Tax | 592 | 757 | 806 | 742 | 622 |
| Profit After Tax | 467 | 577 | 597 | 551 | 474 |
| Operating Profit after Depreciation | 1,061 | 992 | 1,045 | 974 | 883 |
Torrent Pharmaceuticals Ltd Technicals
Support and Resistance
S3 S2 S1 Pivot R1 R2 R3
S1 4,303.67
S2 4,267.43
S3 4,206.77
Pivot 4,364.33
R1 4,400.57
R2 4,461.23
R3 4,497.47
Moving Average
20 SMA 4,416.81
50 SMA 4,271.35
100 SMA 4,209.69
200 SMA 3,938.53
Torrent Pharmaceuticals Ltd Corporate Actions
Torrent Pharmaceuticals Ltd
₹9.0/Share
Announcement Date 29 May 2026
Record Date 29 May 2026
Div Yield 180%
Torrent Pharmaceuticals Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,779.35 | ₹4,26,925.67 |
| Divis Laboratories Ltd | ₹6,594.45 | ₹1,75,061.93 |
| Cipla Ltd | ₹1,397.75 | ₹1,12,910.32 |
| Zydus Lifesciences Ltd | ₹1,085.45 | ₹1,09,221.67 |
| Dr Reddys Laboratories Ltd | ₹1,267.05 | ₹1,05,755.21 |
Torrent Pharmaceuticals Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| HDFC Large Cap Fund | 3.49% |
| SBI Healthcare Opportunities Fund | 3.48% |
| ICICI Pru Nifty Next 50 Index Fund | 1.77% |
| Nippon India Value Fund | 1.54% |
| UTI-Flexi Cap Fund | 1.37% |
Torrent Pharmaceuticals Ltd News
Torrent Pharmaceuticals schedules AGM
On 23 June 2026
04 Jun 2026, 09:42 am
Torrent Pharmaceuticals Ltd spurts 3.06%, rises for third straight session
Torrent Pharmaceuticals Ltd is quoting at Rs 4623.4, up 3.06% on the day as on 12:49 IST on the NSE. The stock is up 45.05% in last one year as compared to a 4.24% fall in NIFTY and a 14.46% fall in the Nifty Pharma index.
25 May 2026, 01:05 pm
Board of Torrent Pharmaceuticals recommends final dividend
Of Rs 9 per share
22 May 2026, 07:25 pm
Torrent Pharmaceuticals to convene board meeting
On 22 May 2026
11 May 2026, 09:48 am
Torrent Pharmaceuticals Ltd up for five straight sessions
Torrent Pharmaceuticals Ltd is quoting at Rs 4369, up 0.14% on the day as on 12:44 IST on the NSE. The stock is up 39.09% in last one year as compared to a 0.65% gain in NIFTY and a 14.52% gain in the Nifty Pharma.
08 May 2026, 01:00 pm
Torrent Pharmaceuticals Ltd Stock Analysis
- Annual revenue for Torrent Pharmaceuticals Ltd increased by 10.46% to ₹10,729.92 crore in FY 2026 from ₹9,713.94 crore in FY 2025.
- Annual Net Profit for Torrent Pharmaceuticals Ltd increased by 16.08% to ₹2,191.59 crore in FY 2026 from ₹1,888.06 crore in FY 2025.
- Promoter Shareholding in Torrent Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 68.31% in December 2025 to 68.31% in March 2026.
- Torrent Pharmaceuticals Ltd delivered a 1-year return of 38.34% compared to the Nifty 50, which provided a return of -4.89% as of the last trading session.
- Torrent Pharmaceuticals Ltd share price moved up by 0.19% from its previous close of INR ₹4,339.90. The latest Torrent Pharmaceuticals Ltd share price is INR ₹4,348.30.
- Torrent Pharmaceuticals Ltd share price today has been at a low of 4,323 and a high of 4,379.90. Over the past 52 weeks, the Torrent Pharmaceuticals Ltd share price has seen a low of 3,108.80 and a high of 4,712.90.
About Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd. is a prominent Indian pharmaceutical company. It engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations. The company operates in the pharmaceutical sector. Additionally, it has a significant presence in various therapeutic areas. This includes gastrointestinal, cardiovascular, gynaecology, diabetology, pain management, and anti-infective segments.
Torrent Pharmaceuticals Ltd. falls under the pharmaceuticals sector. The company was founded in 1959 by U. N. Mehta as Trinity Laboratories. It was later renamed Torrent Pharmaceuticals in 1971. With years of experience, Torrent Pharma has established itself as a key player in the industry.
The headquarters of Torrent Pharmaceuticals Ltd. is located in Ahmedabad, Gujarat, India. The company is promoted by the Torrent Group, with key promoters including Sudhir Mehta and Samir Mehta. They serve as chairman emeritus and chairman of the company. The other managerial promoters of the company include:
Torrent Pharmaceuticals Ltd. is a significant player in the pharmaceuticals sector, with a significant market capitalization. The company is recognized for its innovative solutions and commitment to quality, making it a major player in the industry. Its robust capabilities and extensive product portfolio have further positioned it as a key player in the industry. However, Torrent Pharmaceuticals may not be the largest by market capitalization.
The promoter shareholding in Torrent Pharmaceuticals Ltd. stands at 71.25%, which is entirely held by Torrent Investments Private Limited. This indicates strong promoter commitment to the business.
The registered office of Torrent Pharmaceuticals Ltd. is located at Torrent House, Off Ashram Road, Ahmedabad - 380009, Gujarat, India. Its registrar & transfer agent is TSR Darashaw Consultants Pvt. Ltd.
Torrent Pharmaceuticals Ltd. is a well-established pharmaceutical company in India. The company is known for its comprehensive range of products and strong market presence. Its commitment to innovation and quality has strengthened its position as a trusted name in the industry.
Strategic Market Expansion and Diversification The company's future strategy centres on strategic market diversification across many therapeutic segments. Torrent Pharmaceuticals aims to strengthen its existing strongholds in various therapeutic areas. This includes cardiovascular, women's healthcare, oncology and diabetology. The organization's approach involves developing a balanced portfolio that combines branded and generic pharmaceutical formulations. This ensures resilience and adaptability in rapidly changing market conditions.
A key strategic focus will be geographical expansion, particularly in international markets. By leveraging its strong research and development capabilities, Torrent plans to enhance its global footprint. They are targeting regulated markets like the US, Europe and emerging pharmaceutical markets in Asia and Africa. The company intends to achieve this through a multi-pronged approach. This approach involves strategic partnerships and targeted acquisitions. Also, they localized product development strategies tailored to specific regional healthcare needs.
Technological and Innovation Leadership Torrent Pharmaceuticals Ltd. is committed to positioning itself as a technological leader in pharmaceutical innovation. The company's future strategy emphasizes significant investments in research and development. This is because they focus on developing advanced generic formulations and innovative solutions. Torrent aims to create a robust innovation ecosystem that can generate high value through differentiated pharmaceutical products. This is done by establishing state-of-the-art research facilities and fostering collaborations with academic and research institutions.
The organization plans to leverage emerging technologies to optimize its generic pharmaceutical production. The advanced technological integration will enable more efficient, precise, and cost-effective pharmaceutical development. As a result, it will potentially reduce the time-to-market and enhance the overall product quality.
Sustainability and Operational Excellence Future strategic considerations for Torrent Pharmaceuticals Ltd. include a strong emphasis on sustainability and operational excellence. The company aims to develop environmentally responsible manufacturing processes. Additionally, their goal is to implement advanced quality control mechanisms. Thus, Torrent is investing in green manufacturing technologies and adopting circular economy principles.
Digital Transformation and Healthcare Integration Recognizing the transformative potential of digital technologies, Torrent Pharmaceuticals Ltd. plans to integrate advanced digital solutions across its operations. This includes developing digital health platforms and exploring telemedicine opportunities. They also aim to create patient-centric digital interfaces that help improve healthcare facilities.
Torrent Pharmaceuticals Ltd.'s future strategy represents a sophisticated approach to pharmaceutical development. The company is positioning itself as a pharmaceutical manufacturer and a comprehensive healthcare solutions provider. This is because it is balancing technological innovation, strategic marketing, and digital transformation. The company's forward-looking approach has poised it to redefine the boundaries of pharmaceutical excellence in the coming decades.
Torrent Pharmaceuticals Ltd. falls under the pharmaceuticals sector. The company was founded in 1959 by U. N. Mehta as Trinity Laboratories. It was later renamed Torrent Pharmaceuticals in 1971. With years of experience, Torrent Pharma has established itself as a key player in the industry.
The headquarters of Torrent Pharmaceuticals Ltd. is located in Ahmedabad, Gujarat, India. The company is promoted by the Torrent Group, with key promoters including Sudhir Mehta and Samir Mehta. They serve as chairman emeritus and chairman of the company. The other managerial promoters of the company include:
- Aman Samir Mehta
- Jinesh Shah
- Jinal Mehta
Torrent Pharmaceuticals Ltd. is a significant player in the pharmaceuticals sector, with a significant market capitalization. The company is recognized for its innovative solutions and commitment to quality, making it a major player in the industry. Its robust capabilities and extensive product portfolio have further positioned it as a key player in the industry. However, Torrent Pharmaceuticals may not be the largest by market capitalization.
The promoter shareholding in Torrent Pharmaceuticals Ltd. stands at 71.25%, which is entirely held by Torrent Investments Private Limited. This indicates strong promoter commitment to the business.
The registered office of Torrent Pharmaceuticals Ltd. is located at Torrent House, Off Ashram Road, Ahmedabad - 380009, Gujarat, India. Its registrar & transfer agent is TSR Darashaw Consultants Pvt. Ltd.
Torrent Pharmaceuticals Ltd. is a well-established pharmaceutical company in India. The company is known for its comprehensive range of products and strong market presence. Its commitment to innovation and quality has strengthened its position as a trusted name in the industry.
Future Strategy of the Company
Torrent Pharmaceuticals Ltd. stands at a critical juncture in its evolutionary journey. This is because it is poised to leverage its decades of legacy in pharmaceutical excellence into a transformative future strategy. With a significant market capitalization and a strong promoter shareholding, the company is strategically positioning itself to navigate the complex and dynamic global pharmaceutical landscape. This is accomplished through its innovative approaches, technological integration, and comprehensive market expansion.Strategic Market Expansion and Diversification The company's future strategy centres on strategic market diversification across many therapeutic segments. Torrent Pharmaceuticals aims to strengthen its existing strongholds in various therapeutic areas. This includes cardiovascular, women's healthcare, oncology and diabetology. The organization's approach involves developing a balanced portfolio that combines branded and generic pharmaceutical formulations. This ensures resilience and adaptability in rapidly changing market conditions.
A key strategic focus will be geographical expansion, particularly in international markets. By leveraging its strong research and development capabilities, Torrent plans to enhance its global footprint. They are targeting regulated markets like the US, Europe and emerging pharmaceutical markets in Asia and Africa. The company intends to achieve this through a multi-pronged approach. This approach involves strategic partnerships and targeted acquisitions. Also, they localized product development strategies tailored to specific regional healthcare needs.
Technological and Innovation Leadership Torrent Pharmaceuticals Ltd. is committed to positioning itself as a technological leader in pharmaceutical innovation. The company's future strategy emphasizes significant investments in research and development. This is because they focus on developing advanced generic formulations and innovative solutions. Torrent aims to create a robust innovation ecosystem that can generate high value through differentiated pharmaceutical products. This is done by establishing state-of-the-art research facilities and fostering collaborations with academic and research institutions.
The organization plans to leverage emerging technologies to optimize its generic pharmaceutical production. The advanced technological integration will enable more efficient, precise, and cost-effective pharmaceutical development. As a result, it will potentially reduce the time-to-market and enhance the overall product quality.
Sustainability and Operational Excellence Future strategic considerations for Torrent Pharmaceuticals Ltd. include a strong emphasis on sustainability and operational excellence. The company aims to develop environmentally responsible manufacturing processes. Additionally, their goal is to implement advanced quality control mechanisms. Thus, Torrent is investing in green manufacturing technologies and adopting circular economy principles.
Digital Transformation and Healthcare Integration Recognizing the transformative potential of digital technologies, Torrent Pharmaceuticals Ltd. plans to integrate advanced digital solutions across its operations. This includes developing digital health platforms and exploring telemedicine opportunities. They also aim to create patient-centric digital interfaces that help improve healthcare facilities.
Torrent Pharmaceuticals Ltd.'s future strategy represents a sophisticated approach to pharmaceutical development. The company is positioning itself as a pharmaceutical manufacturer and a comprehensive healthcare solutions provider. This is because it is balancing technological innovation, strategic marketing, and digital transformation. The company's forward-looking approach has poised it to redefine the boundaries of pharmaceutical excellence in the coming decades.
FAQ’s
What is the share price of Torrent Pharmaceuticals Ltd today?
Torrent Pharmaceuticals Ltd share price as on 6 Jun 2026 is ₹ 4348.3
What is the Market Cap of Torrent Pharmaceuticals Ltd?
The market cap of Torrent Pharmaceuticals Ltd stock is ₹1,46,881.94 Cr.
What is the PE Ratio of Torrent Pharmaceuticals Ltd?
The Price to Earnings (P/E) Ratio of Torrent Pharmaceuticals Ltd is 65.18
What is the PB Ratio of Torrent Pharmaceuticals Ltd?
The Price to Book (P/B) Ratio of Torrent Pharmaceuticals Ltd is 16.90
What is the 52 week high of Torrent Pharmaceuticals Ltd Share Price?
The 52 week high of Torrent Pharmaceuticals Ltd share price stands at ₹4,712.90
What is the 52 week low of Torrent Pharmaceuticals Ltd Share Price?
The 52 week low of Torrent Pharmaceuticals Ltd share price stands at ₹3,108.80
How can I buy shares of Torrent Pharmaceuticals Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Torrent Pharmaceuticals Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
